Tomoko Ichiki, Ph.D.

Closed for Enrollment

• A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single-Site Trial to Determine Safety and Efficacy of Chronic Subcutaneous Administration of CD-NP in Renovascular Protection in Heart Failure Patients with Left Ventricular Assist Device Support Rochester, Minn.

  The purpose of this study is to evaluate the safety and effectiveness of a chronic subcutaneous (under the skin) injection of CD-NP, a synthetic peptide (hormone) designed here at Mayo Clinic, on the heart, the blood vessels, the kidneys, and hormone function for people who have heart failure and an LVAD. CD-NP may have protective and preferable effects on damaged heart and kidneys.